NANPING, China, Feb. 4, 2020 /PRNewswire/ -- Happiness Biotech
Group Limited (the "Company" or Nasdaq: HAPP), an innovative
China-based nutraceutical and
dietary supplements producer, announced today that the Company
donated RMB1 million worth of their
most popular immune system boosting products to Shunchang General
Hospital.
Sales for the company's nutraceutical supplement products
targeted to enhance people's immune system such as Cordyceps
Mycelia Oral Liquid has skyrocketed over 100% since the Wuhan Novel
Coronavirus (2019 -nCoV) outbreak in China.
"We are experiencing a dramatic increase in market demand for
our nutraceutical and dietary supplements that help improve
resistance to infections, and we want to contribute and support the
efforts against this outbreak. Our hope is that this donation helps
Shunchang General Hospital in their efforts to combat and treat
patients against the Novel Coronavirus (2019 - nCoV)." said
Mr. Xuezhu Wang, CEO of the
Company.
About Happiness Biotech Group Limited.
Headquartered in Nanping, China, Happiness Biotech Group Limited is an
innovative China-based
nutraceutical and dietary supplements producer focused on the
research, development, manufacturing and marketing of a variety of
products made from Chinese herbal extracts and other ingredients.
The Company's goal is to provide high-quality products to our
consumers. Over the past 14 years, the Company has established a
product portfolio consisting of 32 CFDA registered "Blue-Cap" SKUs
of nutraceutical and dietary supplements products. For more
information, please visit: www.happ.org.cn.
Forward-Looking Statements
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Forward-looking statements are not guarantees of future
performance and involve risks and uncertainties that may cause the
actual results to differ materially from the Company's expectations
discussed in the forward-looking statements. These statements are
subject to uncertainties and risks including, but not limited to,
the following: the Company's goals and strategies; the
Company's future business development; product and service demand
and acceptance; changes in technology; economic conditions;
reputation and brand; the impact of competition and pricing;
government regulations; fluctuations in general economic and
business conditions in China and
assumptions underlying or related to any of the foregoing and other
risks contained in reports filed by the Company with the Securities
and Exchange Commission. For these reasons, among others,
investors are cautioned not to place undue reliance upon any
forward-looking statements in this press release. Additional
factors are discussed in the Company's filings with the U.S.
Securities and Exchange Commission, which are available for review
at www.sec.gov. The Company undertakes no obligation to publicly
revise these forward-looking statements to reflect events or
circumstances that arise after the date hereof.
View original
content:http://www.prnewswire.com/news-releases/happiness-biotech-donated-products-amongst-surging-demand-for-their-immune-systems-products-300997775.html
SOURCE Happiness Biotech Group Limited